SAN DIEGO -- Iapyx Medical, a developer of innovative medical devices, announces a $9 million investment by Tavistock Life Sciences, bringing the companys total funding to more than $12 million. This round of funding coincides with the companys rebranding from Medical Device Group to Iapyx Medical, and its new mission to develop innovative medical devices that reduce hospital-acquired infections. Iapyx plans to use this round of funding to support product development, marketing and sales.
According to the Centers for Disease Control and Prevention (CDC), up to 4 million infections per year are acquired by patients in U.S. hospitals. Hospital-acquired infections add an enormous financial strain of more than $5 billion annually on the healthcare system and are associated with the fourth leading cause of death in the U.S.
Hospital-acquired infections impact one in every 10 patients in the U.S. with approximately 90,000 patients dying annually, said Shehan Dissanayake, CEO of Tavistock Life Sciences. Iapyx Medicals innovative infection control products are uniquely suited to address this critical area of healthcare, and the companys new name and mission reflects this. Most importantly, though, the company is at the center of a movement that will significantly improve the quality of care for patients and safety for healthcare workers.
The Tavistock investment allows us to introduce the Iapyx Medical brand into the marketplace in a meaningful way, and aggressively build on the companys longstanding success designing innovative medical devices, said Joel Smith, president and CEO of Iapyx Medical. This funding gives us an increased ability to develop and market products that will set the standard for hospital care.
The company has re-named itself after Iapyx, a wound healer and battlefield surgeon in Greek mythology who is one of the first people credited with identifying and treating the problem of surgical site infections.
Iapyx Medical develops and manufactures single-use medical devices designed to combat the epidemic of hospital-acquired infections. Today, Iapyx markets two product families that protect both patients and clinicians. The Iso-Line family uses isolation techniques to prevent exposure of patients and clinicians to contaminated devices. The Stable-Line® family of catheter stabilization devices is designed to minimize the risk of site infections, bloodstream and urinary tract infections and other catheter-related complications.
Source: Iapyx Medical
Â
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.